Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells (Q34605718)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells (English)

1 reference

Europe PubMed Central

3 August 2017

Andreas Lundqvist

2

object named as

Andreas Lundqvist

1 reference

Europe PubMed Central

3 August 2017

author name string

Maria Berg

1

1 reference

Europe PubMed Central

3 August 2017

Philip McCoy

3

1 reference

Europe PubMed Central

3 August 2017

Leigh Samsel

4

1 reference

Europe PubMed Central

3 August 2017

Yong Fan

5

1 reference

Europe PubMed Central

3 August 2017

Abdul Tawab

6

1 reference

Europe PubMed Central

3 August 2017

Richard Childs

7

1 reference

Europe PubMed Central

3 August 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

11

1 reference

Europe PubMed Central

3 August 2017

341-355

1 reference

Europe PubMed Central

3 August 2017

3

1 reference

Europe PubMed Central

3 August 2017

Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Molecular basis of the dual functions of 2B4 (CD244).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Prospects for the use of NK cells in immunotherapy of human cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

NK cell and DC interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Large-scale generation of natural killer lymphocytes for clinical application

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Cutting edge: immune cells as sources and targets of the IL-10 family members?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Biology of natural killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Biology and clinical relevance of human natural killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

7 July 2018

Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

26 October 2018

Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

26 October 2018

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736058

26 October 2018

A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19308771

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The IL-12 signature: NK cell terminal CD56+high stage and effector functions

1 reference

https://pubmed.ncbi.nlm.nih.gov/19308771

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19308771

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19308771

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains

1 reference

https://pubmed.ncbi.nlm.nih.gov/19308771

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/14653240902807034

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34605718&oldid=1956787006"